Burger line Burger line Burger line
Logo Logo Logo
Burger line Burger line Burger line
Sign in
Sign in

AbbVie Hits Snag for Parkinson’s Disease Candidate

AbbVie Hits Snag for Parkinson’s Disease Candidate

The FDA said it could not approve AbbVie’s new drug application (NDA) for ABBV-951 (foslevodopa/foscarbidopa), an investigational therapy for advanced Parkinson’s disease, because of concerns about the delivery device.

In a Complete Response Letter to the company, the agency asked for additional information about the infusion pump, which delivers the drug solution subcutaneously.

The FDA did not call for more efficacy and safety trials related to the combination therapy, the company said.

The NDA was supported by results from a late-stage study with 130 participants, in which patients who received ABBV-951 saw meaningful improvements in their “on” time without uncontrolled muscle movements.

AbbVie said it will continue to work closely with the FDA on the issue and resubmit the NDA as soon as possible.

March 27, 2023


0
Cart Subtotal:
Go to cart
You will be able to Pay Online or Request a Quote

We use "cookies*  to ensure the functionality of our website, recognise your browser or device, learn more about your interests, and provide you with essential features and services and for additional purposes, including:

Recognising you when you sign-in to use our services. This allows us to provide you with product recommendations, display personalised content, and provide other customised features and services.
Keeping track of your specified preferences. You may set your preferences through Your Account..
Keeping track of items stored in your shopping basket and personal cabinet.
Conducting research and diagnostics to improve ChemDiv’s content, products, and services.
Delivering content, including ads, relevant to your interests on ChemDiv’s site
Reporting. This allows us to measure and analyse the performance of our services.

By  cookies you give consent to the processing of your personal data, including transfer to third parties. Further information can be found in our privacy policy.

Accept all cookies